Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metagenomic Next-Generation Sequencing for Pulmonary Tuberculosis Diagnosis and Infection Risk Factor Analysis in AECOPD Patients: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Evaluation of TST/C-TST combination for latent tuberculosis infection screening: diagnostic performance and cost-effectiveness compared to TST/IGRAs.BMC infectious diseases · 2026Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
backgroundApproximately 95% of people infected with Mycobacterium tuberculosis do not progress to tuberculosis (TB) disease. Identifying key determinants of TB progression could focus prevention efforts.
methodsContacts of pulmonary TB patients were enrolled in a prospective multi-center cohort study (Regional Prospective Observational Research in Tuberculosis [RePORT]-Brazil) from 2015 to 2019 and followed for 24 months. Empirical review and least absolute shrinkage and selection operator (LASSO) regression, using baseline clinical and laboratory information, were used as dimension reduction techniques to determine factors for inclusion in prediction models. Models were created for: (1) all contacts, (2) contacts interferon-gamma release assay (IGRA)-positive at baseline, and (3) IGRA-positive contacts who did not receive TB preventive therapy (TPT; <30 days isoniazid). Internal validation was performed using bootstrapping.
resultsAmong 1846 contacts of 619 TB index patients, 25 (1.4%) progressed to TB. No TPT was a risk factor for progression to TB among all contacts (mixed-effects adjusted hazard ratio [aHR] = 16.55, 95% confidence interval [CI]: 2.22-124.45). Internal validation with all contacts yielded an area under the receiver operating characteristic curve of 0.80 (95% CI: .72-.86]. Body mass index (BMI) was inversely associated with increased risk of progressing to active TB among IGRA-positive contacts who did not receive TPT (aHR = 0.89, 95% CI: .80-.99). Interferon-gamma release assay-positive contacts with BMI <25 kg/m2 had a 4.14-fold (95% CI: 1.17-14.67) higher risk of progression to TB than IGRA-positive contacts with BMI ≥25 kg/m2: 8.4% versus 2.1%, respectively.
conclusionsBody mass index <25 kg/m2, a readily available biomarker, identified IGRA-positive close TB contacts at high risk of progressing to TB disease. Prioritizing this high-risk group for TB preventive therapy could improve TB prevention efforts. BMI <25 kg/m², a readily available biomarker, identified IGRA-positive close contacts at high risk for progression to TB in a large observational Brazilian cohort. Prioritizing this high-risk group for TB preventive therapy could significantly improve TB prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.